Navigation Links
Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
Date:1/18/2011

NEW YORK and HOBOKEN, N.J., Jan. 18, 2011 /PRNewswire/ -- Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

Charlotte Cunningham-Rundles, M.D., Ph.D., Director of the Allergy Immunology and the Immunology Training Program and Director of the Immunodeficiency Clinic at The Mount Sinai Medical Center, is the lead investigator for a research project focused on distinguishing true Common Variable Immune Deficiencies (CVID) from disorders with more modest immune defects. Dr. Cunningham-Rundles has nearly 30 years experience with clinical immune deficiency disorders with a research focus of human immunodeficiency diseases and immuno-reconstitution.

Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's U.S. subsidiary.

"It is a pleasure to announce Octapharma's support for the valuable research being pursued by the Clinical Immunology Research group at The Mount Sinai Medical Center," said Octapharma USA President

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
2. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
3. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
4. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
5. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
9. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
10. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
11. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
(Date:9/23/2014)... 2014 SOURCE: Solutions from Our ... were made to Rimidi Diabetes and ... with business solutions to challenges faced by patients and ... collaboration between The Hitachi Foundation, Village ... entrepreneurs with the investment capital, mentoring, and support needed ...
(Date:9/23/2014)... Risperdal lawsuits ( http://www.drugbot.com/risperdal/lawsuit/ ) continue ... Liebhard LLP reports. According to an Order issued in ... 19th, the Court has dismissed fraud and negligence per ... on behalf of a man who allegedly developed gynecomastia ... use of Risperdal. In dismissing the Plaintiff’s negligence per ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... They are common suggestions to remedy stress: You just ... out and see people. , Turns out all ... a lot better a new large scale study ... depression, less perceived stress and enhanced mental health and well-being, ... with partners from De Montfort University, James Hutton Institute, and ...
(Date:9/23/2014)... that you may want to get screened and treated ... knife. According to a first-of-its-kind study in the ... journal of the American Society of Anesthesiologists (ASA), patients ... condition prior to surgery are less likely to develop ... , "OSA is a common disorder that affects millions ...
Breaking Medicine News(10 mins):Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:New research suggests sleep apnea screening before surgery 2
... their families to take the following steps:, , ... When you are sick, keep your distance from others to protect them from ... you are sick to help prevent others from catching your illness. Cover your ... and nose with a tissue when coughing or sneezing. It may prevent those ...
... The following is a joint statement from Bruce Yarwood, ... and National Center for Assisted Living (AHCA/NCAL), and Alan ... Home Care: We commend Senators Baucus and Grassley for ... health care policy reforms that will impact every American ...
... April 29 Pennsylvania,s chief agriculture and ... improve national and state food safety initiatives at the ... in Harrisburg. Agriculture Secretary Dennis Wolff and Health Secretary ... in protecting the food supply and responding to outbreaks, ...
... Almost half of those in ICU had deficient levels, study ... levels are deficient in many critically ill patients, new research ... almost half of people in an intensive care unit were ... to be common in seriously ill patients," said study author ...
... PALO ALTO, Calif., April 29 Varian Medical Systems ... from continuing operations of $0.64 per diluted share in ... earnings from continuing operations of $0.57 per diluted share ... research instruments operation, net earnings per diluted share in ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... first quarter ended March 31, 2009, Sangamo reported a consolidated ... to a net loss of $8.0 million, or $0.20 per ... 31, 2009, the company had cash and cash equivalents, marketable ...
Cached Medicine News:Health News:Workforce Swine Flu Pandemic Survival Preparedness Tips For Business 2Health News:National Long Term Care Leaders Praise Overall Baucus Health Reform Effort, Express Specific Concerns Moving Forward 2Health News:Pennsylvania Governor's Food Safety Council Meets to Discuss Food Supply Protection 2Health News:Critically Ill Patients Lack Vitamin D 2Health News:Critically Ill Patients Lack Vitamin D 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 2Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 3Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 4Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 5Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 6Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 7
Bone Curette, 145 mm...
Kevorkian Collector Endocervical Curette is a stainless-steel curette with rounded tip....
Cobb Curettes, 11 inches...
...
Medicine Products: